atenolol

Note: Early reports of pregnancy outcomes in people treated with beta blockers (particularly propranolol) during pregnancy described a relatively high incidence of fetal growth restriction. This appears to be the basis for the C classification of this class of drugs. Since these findings were not from randomised studies, it is not possible to determine whether the described outcomes were due to the therapy or to the disorder for which therapy was prescribed. Subsequent evidence has indicated restricted fetal growth in hypertensive pregnant people treated with atenolol, but better fetal growth in people treated with oxprenolol, than in people treated with methyldopa. No other fetal or neonatal problems have been attributed to beta-blocker therapy in pregnancy, and they are widely prescribed for the treatment of hypertension in pregnancy.